Carma1 Is Important for T-ALL CNS Infiltration and Survival in an Animal Model of T-ALL

Acute lymphoblastic leukemia (ALL) is one of the most common childhood cancer, and can arise from the T or B cell lineage (T-ALL or B-ALL respectively). T-ALL patients have almost 80% cure rate, however leukemic cell migration to the central nervous system (CNS) remains a major therapeutic challenge. Little is known about potential regulators of T-ALL cell migration to the CNS, and identifying new molecules that can drive T-ALL to the CNS may provide new targets for drug therapy to specifically block T-ALL CNS infiltration. Recently it has been shown that a chemokine receptor CCR7 is an essential regulator of T-ALL cell infiltration into the CNS. CCR7 is a homeostatic chemokine receptor expressed on T cells that controls the homing of cells to lymph nodes, including na•ve T cells, dendritic cells, and lymphoma cells. Aberrant CCR7 expression has also been associated with migration of gastric, breast and head and neck cancers. We recently identified the molecule CARMA1 as a signaling mediator that acts downstream of CCR7. We now find that CARMA1 regulates CNS migration in T-ALL. We have established a xenograft model of T-ALL, where we can assess the engraftment of a T-ALL cell line into the NOD/SCID/IL2Rγ2 immunodeficient mice. Using luciferase expressing T-ALL cells lacking CARMA1, we imaged tumor load using the IVIS imaging system. Animals receiving T-ALL cells lacking CARMA1 show a significant delay in the timing of leukemia development as well as longer overall survival compared to animals receiving wild type T-ALL cells (n=25, P value Numerous studies have demonstrated the importance of CARMA1 in normal T cell function. We now find that CARMA1 is also involved in controlling the migration of T-ALL cells to the CNS as well as survival of animals with T-ALL. These results suggest that CARMA1 may provide a novel therapeutic target in T-ALL. Disclosures No relevant conflicts of interest to declare.